基于德尔菲法的高血压风险敏感指标体系的建立

Establishment of an index system of the risk perception of hypertension based on Delphi method

目的应用德尔菲法构建一套比较完整的高血压风险敏感指标体系,为设计行为干预计划,进一步提高高血压患者的治疗依从性提供指导。方法通过查阅相关文献,专家讨论以及结合患者实际情况初步制定4个一级指标,25个二级指标,在此基础上运用德尔菲法,通过对15名专家2轮问卷咨询确定高血压风险敏感指标体系。采用SAS 9.13软件进行统计分析,重要性评价采用x±s进行描述,专家一致协调程度用变异系数及协调系数表示,采用Kendall W检验计算专家协调系数。结果确定的高血压风险敏感指标体系共有心血管风险指标、生化指标、脏器功能损伤、并发症风险和生活方式5个一级指标和23个二级指标;两轮专家的积极系数分别为100%和93.33%;两轮专家咨询的平均权威系数分别为0.89和0.91;两轮专家咨询意见的协调系数分别为0.283和0.435,有统计学意义(P<0.01)。结论本次研究建立的"高血压风险敏感指标体系"具有一定的科学性,合理性,有待今后在高血压患者中进一步验证其效果。

Objective To develop an index system of the risk perception of hypertension among hypertensive patients by the Delphi method, and to provide the direction for designing the behavior inventive plan and improving treatment compliance of hypertension patients. Methods The initial indicator pool including 4 first-level indicators and 25 secondary indicators were developed by referring the relevant literatures, discussion of 15 experts and combination with the actual experience from the hypertensive patients on the basis of Delphi method. The software SAS 9.13 was used to analyze statistical data, the uniform coordination degree of 15 experts was indicated by variation coefficient and coordination coefficient, Kendall W test was used to calculate the coordination coefficient of the experts. Results The indicator pool, which is sensitive to the hypertensive patients, contained five first-level indicators（cardiovascular risk index, the biochemical indicators, organ dysfunction, complication risk and lifestyle） and23 second-level indicators. The positive coefficient for two rounds of the expert interviews were 100% and 93.33% respectively,the average authority coefficient for two rounds of the expert interviews were 0.89 and 0.91, the coordination coefficient for two rounds of the expert interviews were 0.283 and 0.435, P〈0.01. Conclusion ＂The index system of the risk perception of hypertension＂ established in present study has the scientificalness and rationality, which will be validated in hypertension patients for the future.